Factors Affecting the Efficacy of Pramipexole in Patients with Restless Legs Syndrome
Dopamine agonists, particularly nonergot dopamine agonists such as pramipexole, have become the mainstay of therapy for patients with symptoms of restless legs syndrome (RLS). This study was designed to evaluate the factors affecting the efficacy of pramipexole in patients with RLS. Fifty-nine elig...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Tehran University of Medical Sciences
2013-06-01
|
Series: | Acta Medica Iranica |
Subjects: | |
Online Access: | https://acta.tums.ac.ir/index.php/acta/article/view/4427 |
id |
doaj-7a40bfaca12c454c9bc0c782a88d7134 |
---|---|
record_format |
Article |
spelling |
doaj-7a40bfaca12c454c9bc0c782a88d71342020-11-25T03:26:02ZengTehran University of Medical SciencesActa Medica Iranica0044-60251735-96942013-06-015164380Factors Affecting the Efficacy of Pramipexole in Patients with Restless Legs SyndromeMohammad Rezvani0Babak Zamani1Seyed-Mohammad Fereshtehnejad2Department of Neurology, Rasool-e Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.Department of Neurology, Rasool-e Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.Division of Clinical Geriatrics, Department of neurobiology, Care Sciences and Society (NVS), Karolinska Institutet, Stockholm, Sweden. AND Firoozgar Clinical Research Development Center, Iran University of Medical Sciences, Tehran, Iran. Dopamine agonists, particularly nonergot dopamine agonists such as pramipexole, have become the mainstay of therapy for patients with symptoms of restless legs syndrome (RLS). This study was designed to evaluate the factors affecting the efficacy of pramipexole in patients with RLS. Fifty-nine eligible RLS patients referred to neurology clinic of Rasoul-e-Akram Hospital (Tehran, Iran) were recruited in this study. All of the patients received an oral dose of 0.18 mg pramipexole. The severity of RLS symptoms were evaluated including sleep disorder, symptomatic days per week and symptomatic hours per day, both at the beginning and at the end of follow-up time. Different baseline and follow-up variables were also recorded and their relationships with the outcomes were assessed. The mean severity values of different symptoms significantly decreased after treatment with pramipexole (P<0.001). Female gender (P<0.05) and duration of treatment (P<0.05) were significant factors to achieve >50% reduction in symptomatic days per week and symptomatic hours per day. Moreover, the cutoff point of 3.5 mo for duration of treatment could potentially differentiate >50% reduction in severity of sleep disorder from the ones with <50% reduction with sensitivity and specificity of 56.8% and 78.6%, respectively. Our findings show that female gender and duration of treatment were the factors affecting the effectiveness of pramipexole in RLS patients. If tolerated by the patients, a longer duration of treatment with pramipexole is more effective in RLS. https://acta.tums.ac.ir/index.php/acta/article/view/4427EfficacyPramipexoleRestless legs syndrome (RLS)Treatment |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mohammad Rezvani Babak Zamani Seyed-Mohammad Fereshtehnejad |
spellingShingle |
Mohammad Rezvani Babak Zamani Seyed-Mohammad Fereshtehnejad Factors Affecting the Efficacy of Pramipexole in Patients with Restless Legs Syndrome Acta Medica Iranica Efficacy Pramipexole Restless legs syndrome (RLS) Treatment |
author_facet |
Mohammad Rezvani Babak Zamani Seyed-Mohammad Fereshtehnejad |
author_sort |
Mohammad Rezvani |
title |
Factors Affecting the Efficacy of Pramipexole in Patients with Restless Legs Syndrome |
title_short |
Factors Affecting the Efficacy of Pramipexole in Patients with Restless Legs Syndrome |
title_full |
Factors Affecting the Efficacy of Pramipexole in Patients with Restless Legs Syndrome |
title_fullStr |
Factors Affecting the Efficacy of Pramipexole in Patients with Restless Legs Syndrome |
title_full_unstemmed |
Factors Affecting the Efficacy of Pramipexole in Patients with Restless Legs Syndrome |
title_sort |
factors affecting the efficacy of pramipexole in patients with restless legs syndrome |
publisher |
Tehran University of Medical Sciences |
series |
Acta Medica Iranica |
issn |
0044-6025 1735-9694 |
publishDate |
2013-06-01 |
description |
Dopamine agonists, particularly nonergot dopamine agonists such as pramipexole, have become the mainstay of therapy for patients with symptoms of restless legs syndrome (RLS). This study was designed to evaluate the factors affecting the efficacy of pramipexole in patients with RLS. Fifty-nine eligible RLS patients referred to neurology clinic of Rasoul-e-Akram Hospital (Tehran, Iran) were recruited in this study. All of the patients received an oral dose of 0.18 mg pramipexole. The severity of RLS symptoms were evaluated including sleep disorder, symptomatic days per week and symptomatic hours per day, both at the beginning and at the end of follow-up time. Different baseline and follow-up variables were also recorded and their relationships with the outcomes were assessed. The mean severity values of different symptoms significantly decreased after treatment with pramipexole (P<0.001). Female gender (P<0.05) and duration of treatment (P<0.05) were significant factors to achieve >50% reduction in symptomatic days per week and symptomatic hours per day. Moreover, the cutoff point of 3.5 mo for duration of treatment could potentially differentiate >50% reduction in severity of sleep disorder from the ones with <50% reduction with sensitivity and specificity of 56.8% and 78.6%, respectively. Our findings show that female gender and duration of treatment were the factors affecting the effectiveness of pramipexole in RLS patients. If tolerated by the patients, a longer duration of treatment with pramipexole is more effective in RLS.
|
topic |
Efficacy Pramipexole Restless legs syndrome (RLS) Treatment |
url |
https://acta.tums.ac.ir/index.php/acta/article/view/4427 |
work_keys_str_mv |
AT mohammadrezvani factorsaffectingtheefficacyofpramipexoleinpatientswithrestlesslegssyndrome AT babakzamani factorsaffectingtheefficacyofpramipexoleinpatientswithrestlesslegssyndrome AT seyedmohammadfereshtehnejad factorsaffectingtheefficacyofpramipexoleinpatientswithrestlesslegssyndrome |
_version_ |
1724594212661362688 |